TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20923244
Drug: Sitagliptin 50
Normalized name: SITagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 50 mg and metformin 1000 mg co-administration
Study: 15957835
Drug: Shenfu injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu injection (SFI) - 40 ml intravenous injection, once a day for 7 days
Study: 7759696
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil capsules (6 g of n‐3 fatty acids)
Study: 18492834
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil capsules (control)
Study: 12506181
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil capsules
Study: 365665
Drug: Antacid (aluminum‐magnesium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid (aluminum‐magnesium hydroxide tablets, 800 mg seven times per day)
Study: 365665
Drug: Antacid-sulpiride combination
Normalized name: sulpiride
DrugBank: Sulpiride (DB00391)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid-sulpiride combination
Study: 27810902
Drug: TT4‐L (light
Approvals — FDA: no, EMA: no, PMDA: no
Description: TT4‐L (light arm)
Study: 23703722
Drug: Calcium supplements
Normalized name: CALCIUM SUPPLEMENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplements (up to 1000 mg/d)
Study: 11423928
Drug: Heat-treated yoghurt
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-treated yoghurt (<15 bacteria/ml)
Study: 9425382
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily amikacin (7.5 mg/kg, n = 27)
Study: 9425382
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily amikacin (15 mg/kg, n = 27)
Study: 2893638
Drug: Placebo (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral, twice daily for 7 days)
Study: 2910421
Drug: Intensification period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensification period with Cytoxan (cyclophosphamide) and asparaginase after induction; triple-drug chemoprophylaxis of the CNS using methotrexate, hydrocortisone, and cytosine arabinoside.
Study: 2910421
Drug: Intensification period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensification period with Cytoxan (cyclophosphamide) and asparaginase after induction; triple-drug chemoprophylaxis of the CNS.
Study: 21670770
Drug: APC combined
Normalized name: APC-356433
Approvals — FDA: no, EMA: no, PMDA: no
Description: APC combined with photodynamic therapy (PDT)
Study: 11026657
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg/wk for 3 months
Study: 8112439
Drug: Oral terfenadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terfenadine (180 mg q.d., for three days)
Study: 26017871
Drug: Spironolactone 50
Normalized name: spironolactone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 50 mg once a day for 30 days
Study: 14665499
Drug: Highly efficacious
Normalized name: Recombinant human highly phosphorylated acid alpha-glucosidase
DrugBank: Recombinant human highly phosphorylated acid alpha-glucosidase (DB17673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly efficacious treatment (n = 257)
Study: 14665499
Drug: Moderately efficacious
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately efficacious treatment (n = 965)
Study: 14665499
Drug: Mildly efficacious
Normalized name: SIMPLYTHICK GEL ORAL MILDLY THICK 6GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mildly efficacious treatment (n = 891)
Study: 10365809
Drug: Standard-dose ursodeoxycholic
Normalized name: ursodeoxycholate
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose ursodeoxycholic acid (13-15 mg x kg(‐1) x day(‐1))
Study: 10365809
Drug: Low-dose ursodeoxycholic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ursodeoxycholic acid (5-7 mg x kg(‐1) x day(‐1))
Study: 7049706
Drug: Pindolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (10 mg daily)
Study: 22324772
Drug: LipiFlow® Thermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: LipiFlow® Thermal Pulsation System treatment
Study: 21035609
Drug: 5-week couple
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-week couple therapy intervention (n=18)
Study: 18727648
Drug: Greater number
Normalized name: greater celandine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Greater number of previous preventive treatments
Study: 16104447
Drug: Chest physical
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chest physical therapy (CPT) after thoracotomy
Study: 9689556
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (150 IU/kg per dose, increasing to 300 IU/kg per dose, every 3 weeks for 6 months)
Study: 786820
Drug: Sulpiride (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (150 mg daily for the first week, increased to 225 mg in the second week)
Study: 786820
Drug: Chlordiazepoxide (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlordiazepoxide (30 mg daily for the first week, increased to 45 mg in the second week)
Study: 7900628
Drug: Enalapril (angiotensin-converting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (angiotensin-converting enzyme inhibitor)
Study: 19719452
Drug: Single vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single vaccination with modified-live respiratory virus vaccine
Study: 19719452
Drug: Revaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revaccination with modified-live respiratory virus vaccine
Study: 19719452
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no vaccine during finishing phase)
Study: 16698351
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no analgesics)
Study: 15604849
Drug: Nontoxic systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nontoxic systemic drugs
Study: 11309833
Drug: Plasma exchange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma exchange treatment administered every other day for 2 weeks
Study: 11309833
Drug: Crossover to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover to active treatment after failing sham treatment
Study: 11309833
Drug: Crossover to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover to sham treatment after failing active treatment
Study: 9407564
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (NO) at concentrations of 1, 5, 10, and 20 parts per million (ppm)
Study: 7712700
Drug: Standard 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 75 g oral glucose tolerance test (OGTT)
Study: 25581661
Drug: Drink-EtOH adjustments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drink-EtOH adjustments using transdermal alcohol sensor (TAS) readings and self-reported diaries.
Study: 21325151
Drug: Dexmedetomidine (cumulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (cumulative dose, 0.4 μg/kg)
Study: 15910204
Drug: Extended-release mixed
Normalized name: Amphetamine Mixed Salts Extended-Release Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release mixed amphetamine salts (MAS-XR) 10-30 mg doses
Study: 12790363
Drug: Acetazolamide (ACZ)
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide (ACZ) 1000 mg injection
Study: 7773118
Drug: Teachers' administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teachers' administration of questionnaires
Study: 7773118
Drug: Researchers' administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Researchers' administration of questionnaires
Study: 387057
Drug: MK-196 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-196 (10 mg daily)
Study: 387057
Drug: MK-196 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-196 (15 mg daily)
Study: 20705718
Drug: Low-dose hCG
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hCG
Study: 15257812
Drug: Triptorelin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin 0.5 mg (group 3)
Study: 15257812
Drug: Triptorelin 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin 0.1 mg three times (group 4)
Study: 15257812
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized progesterone (group 5)
Study: 11166518
Drug: Apomorphine (APO),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine (APO), 0.01 mg/kg
Study: 6149592
Drug: Antipsychotic drug
Normalized name: antipsychotic drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic drug treatment
Study: 9154767
Drug: Thalidomide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (200 mg orally once per day for four weeks)
Study: 8227504
Drug: Clinician administered
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician administered treatment
Study: 25917060
Drug: Dexamethasone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1 mg/kg)
Study: 24602844
Drug: Delayed antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed antiretroviral treatment
Study: 17766190
Drug: Intravenous meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous meropenem (120 mg/kg/day) and intravenous tobramycin (9-12 mg/kg/day)
Study: 17766190
Drug: Intravenous ceftazidime
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ceftazidime (200-400 mg/kg/day) and intravenous tobramycin (9-12 mg/kg/day)
Study: 6711270
Drug: 50 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml of 1% mepivacaine with adrenaline 1:200,000
Study: 6711270
Drug: 60 ml
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 ml of 1% mepivacaine with adrenaline 1:200,000
Study: 29855172
Drug: ABT-122 120
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-122 120 mg every other week
Study: 29855172
Drug: ABT-122 120
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-122 120 mg every week
Study: 17488511
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) in addition to managed care, consisting of three to six individual sessions of 30 minutes each.
Study: 17488511
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) in addition to managed care.
Study: 2707527
Drug: Hydrocortisone intravenous
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone intravenous (HC i.v.: 100 mg)
Study: 2707527
Drug: Hydrocortisone local
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone local (HC L: 100 mg)
Study: 2707527
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid (5-ASA: 4 g)
Study: 8572357
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg.kg‐1 given 5 min before desflurane increase
Study: 16000582
Drug: 1-hour infusion
Normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour infusion of 100 mg/m2 paclitaxel (Taxol)
Study: 16000582
Drug: 3-hour infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-hour infusion of 100 mg/m2 paclitaxel (Taxol)
Study: 2071554
Drug: Phenytoin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin (100 mg po bid for adults and 50 mg po bid for children)
Study: 26650493
Drug: Supraperiosteal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supraperiosteal injection
Study: 25786679
Drug: TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP block with 20 ml bupivacaine 0.25% with adrenaline 5 μg/ml bilaterally
Study: 22996850
Drug: Weekly information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly information on general health (control group)
Study: 17300719
Drug: Artemisinin compounds
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin compounds
Study: 12871538
Drug: Oral ximelagatran
Normalized name: XIMELAGATRAN
DrugBank: Ximelagatran (DB04898)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ximelagatran (24, 36, 48 or 60 mg twice daily)
Study: 12871538
Drug: Low‐molecular‐weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐molecular‐weight heparin (dalteparin) followed by warfarin
Study: 12844328
Drug: Oral ximelagatran
Normalized name: XIMELAGATRAN
DrugBank: Ximelagatran (DB04898)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ximelagatran
Study: 12871538
Drug: Oral ximelagatran
Normalized name: XIMELAGATRAN
DrugBank: Ximelagatran (DB04898)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ximelagatran and Low‐molecular‐weight heparin (dalteparin) followed by warfarin
Study: 8542165
Drug: Low-dose and
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose and high-dose inhaled terbutaline
Study: 2669441
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg moclobemide
Study: 1792931
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg isocarboxazide
Study: 6359972
Drug: Bupivacaine-fentanyl combination
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bupivacaine-fentanyl combination (0.5% bupivacaine 1.06 ml per metamer + fentanyl 1.70 +/- 0.09 micrograms X kg‐1)
Study: 6359972
Drug: Bupivacaine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine alone (0.5% bupivacaine 1.18 ml per metamer)
Study: 27207001
Drug: AMSA nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMSA nerve block injection at the most common injection site with 3% mepivacaine solution
Study: 27207001
Drug: AMSA nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMSA nerve block injection at the anterior injection site with 3% mepivacaine solution
Study: 20449526
Drug: Speech therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech therapy combined with beclomethasone diproprionate through exclusively nasal inhalation (BDT group)
Study: 20449526
Drug: Only beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only beclomethasone diproprionate through exclusively nasal inhalation (BDI group)
Study: 7755068
Drug: Erythromycin (333
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (333 mg three times a day)
Study: 436200
Drug: Hydralazine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine (100 mg) and Isosorbide Dinitrate (40 mg)
Study: 18346063
Drug: Ultrasound treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound treatment with 5-minute application of liposomal lidocaine cream
Study: 6189335
Drug: Betamethasone valerate
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone valerate (active corticosteroid preparation)
Study: 6189335
Drug: Placebo (basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (basal formulation only)
Study: 22901620
Drug: Alternate-week dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alternate-week dexamethasone (10 mg/m² per day on days 0-6 and 14-20)
Study: 22901620
Drug: Continuous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous dexamethasone (10 mg/m² per day on days 0-20)
Study: 12506171
Drug: FU/LV +
Approvals — FDA: no, EMA: no, PMDA: no
Description: FU/LV + low‐dose bevacizumab (5 mg/kg every 2 weeks)
Study: 12506171
Drug: FU/LV +
Approvals — FDA: no, EMA: no, PMDA: no
Description: FU/LV + high‐dose bevacizumab (10 mg/kg every 2 weeks)
Study: 8137694
Drug: Enhanced preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced preparation intervention (written instructions, reminder to post instructions in the bathroom, toilet seat cover with reminder, nurse-initiated telephone call)
Study: 8137694
Drug: Standard preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preparation intervention (written instructions, telephone number for questions)
Study: 3627588
Drug: 16 dimethyl
Normalized name: Dimethyl Sulfoxide
DrugBank: Dimethyl sulfoxide (DB01093)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 16 dimethyl prostaglandin E2 (PGE2) vaginal suppository
Study: 25087085
Drug: Continuous furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous furosemide infusion (cIV)
Study: 19231632
Drug: Eltrombopag 75
Normalized name: eltrombopag 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 75 mg (dose increase for patients with platelet counts <50,000 after 3 weeks)
Study: 30060980
Drug: AREDS2 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AREDS2 treatment assignment
Study: 22006541
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg GS-9450
Study: 22006541
Drug: GS-9450 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GS-9450 treatment groups
Study: 17109733
Drug: Daclizumab (single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab (single-dose administration)
Study: 15800130
Drug: Control dialysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control dialysate (G)
Study: 12468113
Drug: GHRH administered
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH administered intravenously (50 microg)
Study: 12468113
Drug: GHRH administered
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH administered intranasally (300 microg)
Study: 20207062
Drug: IN ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: IN ketorolac 31.5 mg
Study: 17977171
Drug: 0.5‐mg dinoprostone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5‐mg dinoprostone intracervical (IC) gel
Study: 22605570
Drug: Sulindac (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac (150 mg twice a day)
Study: 934534
Drug: Reserpine (0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reserpine (0.20 mg administered intravenously in standardized cycles of twenty administrations)
Study: 30735073
Drug: EPA (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA (3 g/day)
Study: 31192968
Drug: PASCAL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PASCAL treatment
Study: 28929698
Drug: S. flavescens
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. flavescens gel (test group, 40 cases)
Study: 28929698
Drug: Human recombinant
Normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human recombinant interferon α‐2b gel (control group, 40 cases)
Study: 28929698
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of S. flavescens gel and human recombinant interferon α‐2b gel (combined application group, 40 cases)
Study: 25163441
Drug: 0.6 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 g/kg alcohol (mean peak blood alcohol content of 0.051%)
Study: 25163441
Drug: Energy drink
Normalized name: Boost Energy Drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy drink alone (250 ml)
Study: 23032549
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (200,000 IU initial dose, 200,000 IU one month later, then 100,000 IU monthly for 18 months)
Study: 23032549
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical dosing regimen to vitamin D3)
Study: 16787687
Drug: docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 75 mg/m2 and carboplatin 6 mg/ml min, every 3 weeks (DCb)
Study: 16787687
Drug: vinorelbine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: vinorelbine 25 mg/m2/week plus cisplatin 100 mg/m2, every 4 weeks (VC)
Study: 23336294
Drug: Rivaroxaban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (10 mg once daily started 6-8 hours after surgery)
Study: 9710030
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone (500 mg once a day for 5 days with a 10-day tapering period)
Study: 25186785
Drug: Detectable drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detectable drug concentrations
Study: 9550459
Drug: Nasoenteral tube
Normalized name: Sus scrofa fallopian tube preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasoenteral tube feedings at 125 cc/hour over 11 hours each night in addition to standard post-operative nutritional care
Study: 11519638
Drug: Nicotine treatment
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine treatment
Study: 2541121
Drug: WR-2721 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: WR-2721 and cis-platinum (150 mg/m2)
Study: 2541121
Drug: WR-2721 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: WR-2721 and cis-platinum (120 mg/m2)
Study: 6402
Drug: Timolol ophthalmic
Normalized name: timolol ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol ophthalmic solution 0.5%